Drug company AbbVie ABBV-0.70%decrease; red down pointing triangle has agreed to buy biotech ImmunoGen for $10.1 billion in a new bet on one of the most promising novel drug technologies for ...

AbbVie will buy ImmunoGen for $10.1 billion in cash, it said on Thursday, the latest major drugmaker to acquire a maker of promising "guided missile" cancer therapies as its top-selling treatment ...

AbbVie has placed a high price on that potential, coughing up $700 million for a phase 1 candidate and offering up to $1.225 ...

Nov 30 (Reuters) - AbbVie ABBV.N said on Thursday it will buy drugmaker ImmunoGen IMGN.O for $10.1 billion, boosting its presence in the market for cancer treatments. The drugmaker will pay $31.26 ...

The time is right to expand AbbVie's business with its $10 billion acquisition of ImmunoGen . ImmunoGen is a commercial-stage oncology company focused on developing antibody-drug conjugates (ADCs ...

AbbVie has moved to shore up its pipeline following the loss of patent protection for its top-selling drug with a $10.1 billion deal to buy ImmunoGen and its marketed ovarian cancer drug.

AbbVie announced on Thursday its intent to buy ImmunoGen for $10.1 billion, or $31.26 per share, nearly double ImmunoGen’s share price of $16.06 at market close the day before the deal. More ...

U.S. drugmaker AbbVie said on Monday it will acquire cell therapy developer Capstan Therapeutics in a cash deal worth up to ...

AbbVie’s buy was at a 94.6% premium to ImmunoGen’s closing share price on the last day of trading before the merger was announced, and a 55.9% premium to the highest closing price over a 52 ...

AbbVie Inc. (NYSE:ABBV) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, the “Elahere ...

AbbVie Inc. agreed to acquire ImmunoGen Inc. for a total equity value of $10.1 billion in a move aimed at gaining access to some of the hottest new drugs in the cancer market.

Drug patents don't last forever, so pharmaceutical companies are constantly looking for the next big treatment to broaden their total portfolio of offerings. When it was clear a few years ago that ...